Literature DB >> 1357192

Recognition efficiency of the hepatitis B virus polyadenylation signals is tissue specific in transgenic mice.

S Perfumo1, L Amicone, S Colloca, M Giorgio, L Pozzi, M Tripodi.   

Abstract

The hepatitis B virus genome contains a unique polyadenylation (TATAAA) signal which is differentially utilized in the formation of the various hepatitis B virus transcripts. A head-to-tail multiple-copy insertion of a viral fragment comprising the viral enhancer, the X promoter, the X open reading frame, and the viral poly(A) signal in transgenic mice allowed us to monitor tissue-specific differences in the expression of transcripts initiating from the X promoter. These transcripts are efficiently processed at the first polyadenylation site in the liver, while in the kidney, the brain, and the testis, a portion of the transcripts covers two copies of the transgene, since only the second polyadenylation site is properly recognized. As discussed in this article, this observation suggests a tissue-specific distribution of cellular factors involved in polyadenylation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1357192      PMCID: PMC240185     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Sequences 5' to the polyadenylation signal mediate differential poly(A) site use in hepatitis B viruses.

Authors:  R Russnak; D Ganem
Journal:  Genes Dev       Date:  1990-05       Impact factor: 11.361

2.  Biosynthesis of the reverse transcriptase of hepatitis B viruses involves de novo translational initiation not ribosomal frameshifting.

Authors:  L J Chang; P Pryciak; D Ganem; H E Varmus
Journal:  Nature       Date:  1989-01-26       Impact factor: 49.962

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation.

Authors:  R Bartenschlager; M Junker-Niepmann; H Schaller
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

5.  Leaky transcription termination produces larger and smaller than genome size hepatitis B virus X gene transcripts.

Authors:  W T Guo; J Wang; G Tam; T S Yen; J S Ou
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

6.  Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors.

Authors:  E Seto; P J Mitchell; T S Yen
Journal:  Nature       Date:  1990-03-01       Impact factor: 49.962

7.  Transcription of the human beta interferon gene is inhibited by hepatitis B virus.

Authors:  J S Twu; R H Schloemer
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

8.  Hepatitis B virus X protein transactivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT/enhancer-binding protein-like cis-elements.

Authors:  Y Mahé; N Mukaida; K Kuno; M Akiyama; N Ikeda; K Matsushima; S Murakami
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

9.  Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.

Authors:  F Galibert; E Mandart; F Fitoussi; P Tiollais; P Charnay
Journal:  Nature       Date:  1979-10-25       Impact factor: 49.962

10.  Analysis of processing and polyadenylation signals of the hepatitis B virus surface antigen gene by using simian virus 40-hepatitis B virus chimeric plasmids.

Authors:  C C Simonsen; A D Levinson
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

View more
  14 in total

1.  Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions.

Authors:  C R Madden; M J Finegold; B L Slagle
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Structural and biochemical analysis of Bcl-2 interaction with the hepatitis B virus protein HBx.

Authors:  Tianyu Jiang; Minhao Liu; Jianping Wu; Yigong Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

3.  Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection.

Authors:  Jong-Han Lee; Kwang-Hyub Han; Jae Myun Lee; Jeon Han Park; Hyon-Suk Kim
Journal:  Clin Vaccine Immunol       Date:  2011-04-13

4.  Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma.

Authors:  Neung Hwa Park; Il Han Song; Young-Hwa Chung
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

5.  In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation.

Authors:  O Billet; G Grimber; M Levrero; K A Seye; P Briand; V Joulin
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

6.  Expression of hepatitis B virus X protein does not alter the accumulation of spontaneous mutations in transgenic mice.

Authors:  C R Madden; M J Finegold; B L Slagle
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Preliminary study on the production of transgenic mice harboring hepatitis B virus X gene.

Authors:  Huan-Zhang Zhu; Guo-Xiang Cheng; Jian-Qu Chen; Shu-Yuan Kuang; Yong Cheng; Xin-Li Zhang; Hou-Da Li; Shao-Fu Xu; Jing-Quan Shi; Geng-Sun Qian; Jian-Ren Gu
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

Review 8.  Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis.

Authors:  Shogo Ohkoshi; Haruka Hirono; Kazuhiko Watanabe; Katsuhiko Hasegawa; Masahiko Yano
Journal:  World J Hepatol       Date:  2015-12-08

9.  HBVRegDB: annotation, comparison, detection and visualization of regulatory elements in hepatitis B virus sequences.

Authors:  Nattanan Panjaworayan; Stephan K Roessner; Andrew E Firth; Chris M Brown
Journal:  Virol J       Date:  2007-12-17       Impact factor: 4.099

10.  2',3'-cyclic nucleotide 3'-phosphodiesterases inhibit hepatitis B virus replication.

Authors:  Hui Ma; Xing-Liang Zhao; Xue-Yan Wang; Xing-Wang Xie; Jin-Chao Han; Wen-Li Guan; Qin Wang; Lin Zhu; Xiao-Ben Pan; Lai Wei
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.